Full history for every metric is available with a Kvantra account
Mainz Biomed B.V. (MYNZ)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Operating profit | $m | -13 | -15 | |||||
| Net profit | $m | -1 | -12 | -26 | -26 | -22 | -16 | -19 |
| EPS reported | $ | -2.70 | -1.05 | |||||
| Operating cashflow per share | $ | -1.83 | -0.55 | |||||
| Capex per share | $ | 0.00 | 0.01 | |||||
| FCF per share | $ | -1.83 | -0.56 | |||||
| Free cash flow | $m | -11 | -10 | |||||
| Net debt | $m | 0 | -13 | |||||
| Book value equity | $m | 1 | - | |||||
| Book value per share | $ | 0.11 | - | |||||
| Number of shares | m | 6 | 17.85 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 10.47 | 3.15 | |||||
| P/S LTM | x | 12.51 | 58.68 | |||||
| P/FCF LTM | x | -0.61 | -1.46 | |||||
| EV/EBITDA LTM | x | -0.65 | -0.09 | |||||
| EV/Sales LTM | x | 15.64 | 5.25 | |||||
| Earnings Yield LTM | % | -241.36% | -29.46% | |||||
| FCF Yield | % | -163.49% | -68.30% | |||||
| Quality | ||||||||
| ROE | % | -2526.6% | -179.80% | |||||
| ROIC | % | -420.12% | -75.12% | |||||
| Operating margin | % | -2513.4% | -6109.7% | |||||
| Gross margin | % | -42.07% | 33.72% | |||||
| FCF/Sales | % | -2044.5% | -4008.0% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -39.92% | -62.06% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.27 | - | |||||
| Net Debt/EBITDA | x | -0.13 | 0.89 | |||||
| EBIT/Net interest | x | 36.15 | 683.39 | |||||
| Net debt/market cap | % | 4.97% | -91.05% | |||||
| Net debt/Equity | x | 0.52 | - | |||||
| Gross debt/equity | x | 4.01 | - | |||||
Company overview
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mainz Biomed B.V. (MYNZ)
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free